News

Among the many sleeping problems facing children with Angelman syndrome, insomnia and the circadian rhythm disturbances that fracture sleep are the most frequent and troublesome, according to a survey of parents and caregivers. Sleep disturbances affect a child’s behavior at home and school, the adults noted, while depriving parents…

Angelman syndrome patients who experience falls or sleep problems tend to have worse quality of life, according to a survey of caregivers. “Significant findings from this caregiver study revealed that the ability to walk and ambulate is associated with higher [quality of life], whereas falls, problems with sleep, and…

The first patient organization for those living with Angelman syndrome in the Middle East and North Africa — a geographic region commonly known as MENA — has been established in Dubai, in the United Arab Emirates. The MENA Angelman Association will cover more than 20 countries with an area of…

The protein Ube3a, whose defect causes Angelman syndrome, helps regulate connections between brain cells during development. That’s according to the study, “Presynaptic Ube3a E3 ligase promotes synapse elimination through down-regulation of BMP signaling,” which was published in Science. “Our findings reveal the physiological role of Ube3a…

A $5 million gift is supporting a University of California San Diego (UC San Diego) gene therapy initiative aimed at finding novel treatments for children and adults with genetic disorders. The launch of the Gene Therapy Initiative, made possible by the donation from the Nancy and Geoffrey Stack Foundation,…

Combining outcomes at clinic visits with those of at-home monitoring may be an effective way of determining an experimental treatment’s effectiveness in Angelman syndrome (AS) clinical trials, researchers report. Overall adherence in a yearlong observational study of AS patients “indicate that the key clinical aspects of AS identified by…

OV101 (gaboxadol) fails to ease disease severity in children with Angelman syndrome (AS), according to recently published final results from the Phase 3 NEPTUNE trial. The findings are overall consistent with previously reported top-line trial data from the treatment’s developer Ovid Therapeutics, which prompted the company…

Two new standardized tools to measure the severity of Angelman syndrome (AS) in children — one based on clinician assessments and another on caregiver reports — have been developed and are in use in clinical trials to measure the disease’s severity and evaluate the impact of potential treatments. These…

GTX-102, a gene therapy for Angelman syndrome, continues in a clinical trial to be safe and show benefit when taken for over a year, with the longest period being nearly two years, according to its developer, Ultragenyx Pharmaceutical. No new serious side effects or reports of leg weakness…

Angelman Syndrome Foundation Canada (ASF Canada), formerly the Canadian Angelman Syndrome Society (CASS), officially opens on Oct. 21 with the Stronger Together Charity Ball, an evening of celebration and inspiration. The black-tie event, which is intended to raise awareness about Angelman syndrome, also kicks off ASF Canada’s affiliation…